Bio-Rad Laboratories Class B
BIO.B
8 hedge funds and large institutions have $8.2M invested in Bio-Rad Laboratories Class B in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 0 closing their positions.
14% more funds holding
Funds holding: 7 → 8 (+1)
4% more capital invested
Capital invested by funds: $7.86M → $8.2M (+$348K)
0.01% more ownership
Funds ownership: 0.51% → 0.52% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$155K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CL
1
CSS LLC
Chicago,
Illinois
| $6.92M | – | – | – |
|
|
CF
2
Copperwynd Financial
Scottsdale,
Arizona
| $581K | – | – | – |
|
3
Renaissance Technologies
New York
| $337K | – | – | – |
|
4
UBS Group
Zurich,
Switzerland
| $179K | – | – | – |
|
|
5
Morgan Stanley
New York
| $163K | +$155K | +522 | New |
|
6
Wells Fargo
San Francisco,
California
| $17K | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $2K | – | – | – |
|
BIO.B Hedge Fund Activity: Q2 2019 in Review
8 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class B (BIO.B) for Q2 2019, worth a combined $8.2M — up 4.4% from $7.86M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BIO.B positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $155K.
- 8 institutional investors held Bio-Rad Laboratories Class B (BIO.B) as of Q2 2019, up from 7 in Q1 2019.
- Funds reported $8.2M of Bio-Rad Laboratories Class B stock for Q2 2019, up 4.4% quarter-over-quarter.
- 1 fund opened new Bio-Rad Laboratories Class B positions in Q2 2019 and 0 closed out, a net change of +1 holder.
- The largest Bio-Rad Laboratories Class B buyer in Q2 2019 was Morgan Stanley, an estimated $155K added.
Based on aggregated 13F filings for Q2 2019.